Zogenix, Inc. (ZGNX) Investment Research Dashboard
About Zogenix, Inc. (ZGNX) stock analysis
Get live ZGNX stock price $26.68, comprehensive Zogenix, Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time ZGNX stock data and investment insights.
Loading chart data...
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Zogenix, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for rare diseases within the United States, striving to profoundly improve the quality of life for affected patients and their fa...
Company Information
- CEO
- Stephen Farr
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 327
Contact Information
- Website
- https://www.zogenix.com
- Address
- 5959 Horton St Ste 500
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Zogenix, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for large-cap equities
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Zogenix, Inc.
- ⚠Investors should consider how Zogenix, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
P/E Ratio (TTM)
-6.56
Beta
0.90
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare ZGNX with peer companies:
- Price
- $44.15+0.00% (1D)
- Market cap
- 915.89M
- Price
- $28.00+0.00% (1D)
- Market cap
- 1.77B
- Price
- $29.06+0.00% (1D)
- Market cap
- 1.27B
- Price
- $9.10+0.00% (1D)
- Market cap
- 1.20B
- Price
- $2.34+0.00% (1D)
- Market cap
- 1.14B
- Price
- $21.55+0.00% (1D)
- Market cap
- 1.83B
- Price
- $12.50+0.00% (1D)
- Market cap
- 1.33B
- Price
- $16.87+0.00% (1D)
- Market cap
- 1.06B
- Price
- $11.13+0.00% (1D)
- Market cap
- 994.04M
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
78/100 ⭐⭐⭐⭐⭐
- Overall
- +0.7%
- NYSE
- +0.6%
- NASDAQ
- +0.7%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +2.2% | +3.1% | +4.3% | 19.3 | 98/100⭐⭐⭐⭐⭐ |
| Healthcare | +0.7% | +1.3% | +1.6% | 24.1 | 78/100⭐⭐⭐⭐⭐ |
| Communication Services | +1.4% | -0.7% | +2.9% | 22.2 | 74/100⭐⭐⭐⭐⭐ |
| Consumer Defensive | -0.2% | +1.8% | +0.7% | 29.7 | 64/100⭐⭐⭐⭐ |
| Basic Materials | +0.4% | +1.2% | -0.2% | 25.2 | 61/100⭐⭐⭐⭐ |
| Real Estate | -0.5% | +0.0% | -2.5% | 29.2 | 43/100⭐⭐⭐ |
| Energy | -2.1% | -3.7% | -4.1% | 19.1 | 39/100⭐⭐ |
| Utilities | -1.0% | +0.0% | -4.4% | 26.8 | 37/100⭐⭐ |
| Industrials | +0.6% | +0.4% | -9.9% | 30.1 | 23/100⭐ |
| Consumer Cyclical | +0.5% | -1.5% | -5.8% | 43.0 | 18/100⭐ |
| Technology | +0.6% | -1.6% | -7.2% | 40.7 | 15/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-28.